Menin
39 programs · 38 companies
Programs
39
Companies
38
Active Trials
30
Targeting Menin
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | DLBCLEwing Sarcoma | |
| NVS-1475 | Novartis | Phase 2 | MGPBC | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | ADPKDFabry | |
| Olpainavolisib | Moderna | Phase 1 | CLLHNSCC | |
| Cevimavacamten | Denali | NDA/BLA | FLRSV | |
| Sovacagene | Relay Therapeutics | Phase 1/2 | Prostate CaSMA | |
| ZEA-9089 | Zealand Pharma | Phase 2/3 | Melanoma | |
| SND-5878 | Syndax | NDA/BLA | SMA | |
| Sovaderotide | Chugai | Phase 2/3 | SCLCAsthma | |
| Lisosotorasib | UCB | NDA/BLA | Wilms | |
| DAN-IIT-673 | Dana-Farber | Preclinical | RA | |
| SWO-IIT-832 | SWOG | Approved | WM | |
| IMM-8177 | ImmunoGen (AbbVie) | Phase 1 | RSV | |
| MGX-6815 | Metagenomi | Phase 2 | Gastric Ca | |
| ELE-7041 | Elevation Onc | Preclinical | DLBCLADHD | |
| Tezerapivir | ARS Pharma | Preclinical | Gastric CaMG | |
| ALR-3772 | Aileron Therapeutics | Phase 3 | Breast Ca | |
| 601-7487 | Shanghai Pharma | Phase 2 | LGSAS | |
| Elrazanubrutinib | Arena (Pfizer) | NDA/BLA | SCDWet AMD | |
| MYO-1420 | MyoKardia (BMS) | Preclinical | CLL | |
| BIO-708 | BioNova | Phase 2/3 | DLBCLMCC | |
| ALD-6159 | Aldel Bio | Phase 1 | MyelofibrosisIPF | |
| INT-9034 | Intercept (Alfasigma) | Phase 1/2 | NASH | |
| TAI-4908 | Taiho Pharma | Phase 3 | Endometrial CaMDS | |
| NOI-8348 | Noile-Immune | Preclinical | FLFabry | |
| Nidainavolisib | Curocell | Approved | WilmsPSP | |
| TOR-2843 | Torrent Pharma | Phase 1/2 | PVACC | |
| MRK-9679 | Merck KGaA | NDA/BLA | MesoGBM | |
| Liracagene | ADC Therapeutics | NDA/BLA | CLL | |
| GRF-2905 | Grifols SA | Phase 1 | EoEMCL | |
| Lisozumab | Hanmi Pharm | Phase 2/3 | Endometrial CaAS | |
| Gelicapivasertib | Lupin Limited | Preclinical | SCLCUC | |
| KAR-IIT-216 | Karolinska Inst | Phase 1 | ADHD | |
| TAT-IIT-383 | Tata Memorial Hosp | Phase 3 | PV | |
| TAT-IIT-583 | Tata Memorial Hosp | Phase 3 | GA | |
| SIR-IIT-682 | Siriraj Hospital | Preclinical | Meso | |
| Riluderotide | CTTQ Pharma | Phase 2/3 | Atopic DermObesity | |
| ADA-4330 | Adamed | Approved | MMCKD | |
| ZTS-7862 | Zoetis | Phase 1/2 | MDS |